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Transthyretin (TTR) is a major amyloid ﬁbril protein in certain systemic forms of amyloidosis. It is a plasma protein, mainly
synthesized by the liver but expression occurs also at certain minor locations, including the endocrine cells in the islets of
Langerhans. With the use of immunohistochemistry and in situ hybridization, we have studied the distribution of transthyretin-
containing cells in islets of Langerhans in type-2 diabetic and nondiabetic individuals. TTR expression was particularly seen in
alpha (glucagon) cells. Islets from type-2 diabetic patients had proportionally more transthyretin-reactive islet cells, including beta
cells.AweaktransthyretinimmunoreactioninIAPP-derivedamyloidoccurredinsomespecimens.Inseedingexperimentsinvitro,
we found that TTR ﬁbrils did not seed IAPP while IAPP ﬁbrils seeded TTR. It is suggested that islet expression of transthyretin
may be altered in type-2 diabetes.
Copyright © 2008 G. T. Westermark and P. Westermark. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Deposition of amyloid is the single, most common, and
characteristic morphological lesion in islets of Langerhans
in individuals with type-2 diabetes. Some degree of islet
amyloidosis is found in at least 95% of such patients [1]. In
about two thirds of the cases, more than 50% of the islets
areaﬀected.Astheamyloidamountincreases,thepercentage
of beta cells decreases [2, 3]. The amount of amyloid can be
considerable in a single islet, more or less converting it into
amyloid.
The islet amyloid ﬁbril consists of islet amyloid polypep-
tide (IAPP; amylin) which is a 37-amino acid residues
beta cell hormone, stored together with insulin in secretory
vesicles and released with this hormone. The normal molar
ratio between IAPP and insulin in human is less than 5%.
Although IAPP is a very ﬁbrillogenic peptide in vitro, it does
notﬁbrillizeinnormalislets,possiblyduetointeractionwith
insulin which is a potent inhibitor of IAPP ﬁbril formation
[4–6].
It is not understood why IAPP forms amyloid deposits in
conjunctionwithtype-2diabetes.AnoverexpressionofIAPP
does exist in obese type-2 diabetic patients [7], but this alone
is most probably not suﬃcient for amyloid formation. Thus,
transgenic mice, highly overexpressing human IAPP, do not
develop islet amyloidosis unless manipulated in other ways,
for example, feeding a diet high in fat [8–10]. Therefore,
additional factors may operate in the amyloidogenesis.
The amyloid diseases constitute a biochemically and
clinically diverse group of disorders. Each amyloid disease
is characterized by one speciﬁc amyloid ﬁbril protein and
u n t i ln o w ,m o r et h a n2 5p r o t e i n sh a v eb e e nf o u n di nh u m a n
amyloidosis [11]. Aggregation of a peptide to amyloid-like
ﬁbrils in vitro is a nucleation-dependent process in which
a nucleus is formed before ﬁbrils start to grow [12–14].
The nature of this nucleus is not fully understood and the
time it takes for its formation, known as the lag phase,
varies depending on protein, concentration, temperature,
and other factors. As soon as a nucleus is present, the growth
of amyloid-like ﬁbrils can occur rapidly. Seeding a solution
with preformed ﬁbrils greatly enhances the ﬁbrillogenesis
and reduces the lag phase sometimes close to zero. It is
assumed that protein monomers add to the free end of the
ﬁbrils. This mechanism is believed not only to work in vitro2 Experimental Diabetes Research
butalsoinvivoandmaybeanimportantreasonwhyamyloid
inﬁltration in systemic amyloidoses spreads rapidly as soon
as it has started. Seeding capability is generally very speciﬁc
and already minor variations in the protein eﬃciently block
the addition of new monomers [15]. However, in vitro
experiments have shown that preformed ﬁbrils made from
heterologous amyloid ﬁbril proteins sometimes can act as
seed [16]. Heterologous amyloid ﬁbrils may also act as
eﬃcient seed in two diﬀerent murine models of systemic
amyloidosis [17, 18]. That means, at least in theory, that
ﬁbrils of one biochemical nature may be a risk factor
for the formation of amyloid deposits of another kind of
amyloidosis.
InadditiontoIAPP,anothermajoramyloidﬁbrilprotein,
transthyretin (TTR), is expressed in considerable amount in
thepancreas[19,20].TTRisthemajoramyloidﬁbrilprotein
in several systemic familial forms of amyloidosis and in the
prevalent senile systemic amyloidosis [21]. Similar to other
types of systemic amyloidosis, most of the ﬁbril protein in
these amyloidoses is derived from the plasma pool and the
major expression site of TTR is the liver [22, 23]. There are,
however, a few minor sites of TTR gene expression and one
of them is the endocrine pancreas [24, 25]. The function
of TTR in these localized cells is not known. Furthermore,
the possible eﬀect on amyloidogenesis by these additional
expression sites has not yet been studied.
Against this background, we questioned whether IAPP-
amyloid could induce TTR-ﬁbril formation, and also
whether deposition of TTR-amyloid in the pancreas leads
to islet amyloidosis, either by deposition of ﬁbrils from
TTR or from IAPP. Since we were not aware of any study
of islet TTR in type-2 diabetes, another aim was to study
the immunoreactivity of islet alpha (glucagon) and beta
(insulin) cells in diabetic and nondiabetic individuals.
2. MATERIAL AND METHODS
Paraﬃn-embedded pancreatic material (corpus or cauda)
from 6 individuals with type-2 diabetes and from 10
nondiabetic individuals was available in the laboratory
ﬁles. The inclusion criterion was that specimens had been
taken within 12 hours after death. They were ﬁxed in
buﬀeredneutral4%formaldehydesolutionandembeddedin
paraﬃn. Formalin-ﬁxed and paraﬃn-embedded tissue from
the pancreatic body was also obtained from two patients
with long history of familial TTR-amyloidosis associated
with a V30M-mutation in the TTR gene. Adjacent 5μm
sections were taken for alkaline Congo red staining [26]a n d
for immunohistochemistry. The study was approved by the
Ethical Committee at Uppsala University Hospital.
Antibodies against insulin (guinea pig) and glucagon
(rabbit) were purchased from DAKO (Glostrup, Denmark).
Rabbit antisera (A110) against rat/mouse IAPP, which shows
complete cross-reactivity with human IAPP [27] and against
a recombinant C-terminal fragment (aa 50–127; antiserum #
A1898) of human TTR, have been characterized previously
[28]. A rabbit antiserum, A1899, was raised against a high-
molecular fraction from a gel separation of ATTR ﬁbrils
from an individual with senile systemic amyloidosis. This
20μm
Figure 1:Isletinatype-2diabeticpatient.Mostoftheislethasbeen
converted into amyloid; Congo red, bar 20μm.
antiserum recognizes TTR amyloid, but is unreactive with
AL and AA amyloid in Western blot analysis. Immuno-
histochemistry was performed with the antisera diluted
1:2000 using the biotin-streptavidin system. Sections were
developed with 3,3 -diaminobenzidine-tetrahydrochloride
(DAB). Double immunolabeling was performed with anti-
bodies against glucagon and TTR or insulin and TTR,
visualized with rabbit, mouse, or Guinea pig secondary
antibodies conjugated to Alexa 488 (analyzed in blue light)
or Alexa 546 (analyzed in green light) (Molecular Probes,
E u g e n e ,O r e ,U S A ) .
For controls, sections were treated with antiserum pre-
absorbed with TTR. Cross-reactivity between TTR or IAPP
and glucagon was ruled out by dot blot analysis for which
TTR,IAPP,andglucagonweredissolvedat3μg/wellin0.1M
sodium carbonate buﬀe r ,p H9 . 8 ,s p o t t e do nan i t r o c e l l u l o s e
membrane and incubated with the antisera and developed
with biotin-streptavidin followed by DAB. This showed
that no cross-reactivity existed between IAPP and TTR or
glucagon and TTR.
In order to test the speciﬁcity of the two TTR antisera,
sections from an “amyloid array” were used. In this, 1mm
thick cylinders from amyloid-containing tissues had been
embedded in one block. The array contained the following
types of amyloid: AA-amyloid (7 cases, 9 tissues), AL-
amyloid (7 cases, 9 tissues), ATTR-amyloid (6 cases, 3
tissues), Aβ-amyloid (1 case, brain), and IAPP-amyloid (3
cases, pancreas).
2.1. Degreeofisletamyloidosis
The number of islets with and without amyloid deposits
was determined in Congo red stained sections, analyzed in
polarized light. Usually, at least 50 islets were scrutinized in
each section.
2.2. LocalizationofTTRinisletsoflangerhans
A cDNA library was constructed from human liver with the
aid of a cDNA synthesis kit (Amersham Bioscience, Uppsala,
Sweden). A 237-nucleotide long fragment corresponding to
amino acid residues 2–106 of TTR was ampliﬁed by poly-
merase chain reaction. The achieved fragment was ligatedG. T. Westermark and P. Westermark 3
20μm
(a)
20μm
(b)
(c) (d)
Figure 2: Normal human islets immunolabeled with antisera against: (a) transthyretin and (b) glucagon. In (c) is shown a normal human
islet, subjected to in situ hybridization with a TTR probe, visualized with immunohistochemistry. Note that positive cells have a distribution
indicative of glucagon cells. Bar 20μm. (d) shows a part of a glucagon cell with typical granules. The section was double immunolabeled
for glucagon (10nm gold particles) and TTR (5nm gold particles). Immunolabeling for both these substances is seen on the granules, bar
500nm.
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Figure 3: In (a), (b), and (c), an islet double labeled for glucagon (red) and TTR (green). Yellow color indicates colocalization. A large
number of islet cells show TTR but not glucagon content. The islet in (d) is double labeled for insulin (green) and TTR (red). Many beta
cells exhibit both TTR and insulin immunoreactivity (yellow). The amyloid (A) is weakly labeled for TTR. Bar (a)–(c) 25μm, (d) 200μm.4 Experimental Diabetes Research
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Figure 4: Amyloid-rich islet from a type-2 diabetic individual, in (a) immunolabeled for TTR, and in (b) for insulin. Note virtually identical
distribution of immune reactive cells. No nuclear staining, bar 20μm.
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Figure 5: In (a) is shown an islet from a type-2 diabetic individual. There is pronounced IAPP amyloid inﬁltration, weakly labeled with
antibodies against TTR. (b) shows a small islet in a nondiabetic individual with familial TTR-amyloidosis. There are heavy deposits of
TTR-amyloid outside the islet but no islet amyloid. A = amyloid. Immunolabeled with antiserum against TTR.
into the multiple cloning site of pGEM4Z (Promega, SDS-
Biosciences, Falkenberg, Sweden). The vector was linearized
in front of the SP6 or T7 promoters and digoxigenin-labelled
RNA probes were produced according to the manufacturer
(Roche, Bromma, Sweden). In situ hybridization was per-
formed as described [29].
Forultrastructuralstudies,pancreatictissuewasavailable
from one patient with type-2 diabetes and one normal
control, ﬁxed in 2% glutaraldehyde in phosphate buﬀer and
embedded in epon. For double immunolabeling, ultrathin
sections on formvar-coated nickel grids, were incubated with
the primary antibodies (rabbit anti TTR50-127) and mouse
antiglucagon (DAKO). TTR was visualized with 5nm gold
particles and glucagon with 10nm gold particles (British
Biocell, Cardiﬀ,U K ) .
2.3. Seedingexperiments
Full length human TTR was a kind gift from Dr. Tom
Pettersson (Danderyd, Sweden) and human IAPP was syn-
thesized by Keck Laboratory, New Haven, Connecticut. TTR
(0.5mg) and IAPP (0.125mg) were dissolved separately in
25μl methyl sulfoxide (DMSO). To the solutions, 100μl
distilled water was added. After incubation for 2 days at
room temperature, 0.5μl samples were taken from each
and studied electron microscopically (negative contrast) for
presence of amyloid-like ﬁbrils. Since typical ﬁbrils were
seen in both solutions, they were diluted to 2ml with
0.05M sodium phosphate buﬀer, pH 7.2. To wells of a 96-
well plate with either 25μl of TTR or IAPP ﬁbrils, 50μm
newly dissolved TTR or IAPP in 0.05M phosphate buﬀer
containing 2% DMSO was added, followed by thioﬂavin T
to 10μM. The ﬁnal volume was 100μl. Fluorescence was
measured every 20 minutes in a ﬂuoroscan as described [28].
2.4. Statistics
Valuesaregivenasmean ± SD.Comparisonbetweengroups
was performed with Mann Whitney test.
3. RESULTS
In the pancreata of all individuals with type-2 diabetes
and in 7 out of 10 individuals without diabetes, amyloidG. T. Westermark and P. Westermark 5
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Figure 6: In vitro seeding and cross-seeding experiments with TTR
and IAPP measured with thioﬂavin T. Preformed ﬁbrils of IAPP
s e e d e dTT R( b l u ec i r c l e s )a n dI A P P( r e dt ri a n gl e s ,i n s e rt ) .N oo t h e r
increase in signals occurred. Thus, TTR ﬁbrils did not seed IAPP
(red circles).
was found in islets of Langerhans. All of the diabetic
individuals had a very pronounced islet amyloidosis with
some islets with little remaining endocrine cells (Figure 1).
In the nondiabetic patients, usually only small amyloid
deposits were detected but in three individuals amyloid
aﬀected more than 20% and in one as much as 38% of
the islets. Comparison of the percentage of aﬀected islets
in the two groups when only individuals with some degree
of islet amyloidosis were included, showed that signiﬁcantly
more islets contained deposits in the diabetic individuals
(98 ± 3% and 13 ± 14%, P = 0.001). The islet amyloid had
typical staining properties with Congo red and was strongly
labeled with antiserum against IAPP (not shown).
3.1. Hormoneandtransthyretinreactivityinisletcells
ofnon-diabeticindividuals
In sections of pancreata without amyloid from nondia-
betic individuals, both antisera A1898 and A1899 labeled
islet cells in a similar way. A strong reaction was seen
in all islets with cells with a preferentially peripheral
distribution (Figure 2(a)) When compared with sections
immunostained for glucagon, an identical distribution was
seen (Figure 2(b)). In addition, the majority of remaining
islet cells, mainly beta cells, were also labeled but only weakly
(Figure 2(a)).Insituhybridizationexhibitedclearexpression
of TTR in cells which had a distribution of alpha cells
only and no certain reactivity was found with beta cells
(Figure 2(c)). Electron microscopically glucagon cells are
characterized by secretory vesicles with a rounded electron
dense core often situated somewhat eccentrically on the rest
of the granule. Glucagon immunoreactivity occurred in both
these areas of the granules while TTR labeling was mainly
seen in the less electron dense parts of the alpha cell granules
(Figure 2(d)). Small gold particles were also seen in the
translucent areas of beta cells but only to a small extent (not
shown.). Antisera against insulin and IAPP labeled normal
b e t ac e l l sa sd e s c r i b e d[ 30].
Double labeling for glucagon and TTR showed that all
glucagoncellsalsoexhibitedTTRimmunoreactivity(Figures
3(a) and 3(b)). In addition, a large number of islet cells,
negative for glucagon, showed an evident TTR-reactivity
(Figure 3(c)). Colocalization of insulin and TTR was seen in
m a n y ,b u tn o ta l l ,b e t ac e l l s( Figure 3(d)).
3.2. Endocrinecellsinisletswithamyloid
Both insulin and glucagon immunoreactive cells were identi-
ﬁed in islets will all degrees of amyloid deposits. As described
earlier [31, 32], beta cells in amyloid-laden islets generally
were devoid of IAPP-immunoreactivity. Many cells showed a
strong labeling with antibodies against TTR. From adjacent
sections, stained for TTR, insulin, and glucagon, it was
obvious that not only alpha cells but also beta cells were
strongly TTR-positive (Figure 3).
3.3. Transthyretinreactivityinisletamyloid
Islet amyloid from diabetic and nondiabetic individuals
exhibited a strong immunolabeling with antiserum against
IAPP (not shown). Since we have shown previously that
commercially available antibodies against TTR often do not
recognize TTR in ﬁbrillar (i.e., amyloid) form, we developed
two diﬀerent rabbit antisera which both strongly labeled
cellular TTR and TTR in amyloid. The two TTR antisera
labeled islet amyloid weakly in some cases (Figures 3(d)
and 5(a)). This staining was even and no areas with strong
reaction were seen. In the electron microscopic study, IAPP
antiserumlabeledamyloidinthediabeticcase,butnocertain
binding of TTR antibodies to ﬁbrils was seen. In order to
study the speciﬁcity of the reaction in amyloid, we used an
amyloid array with tissues from several patients in one block.
The two TTR antisera showed reaction only with amyloid
of known TTR origin (i.e., Swedish familial amyloidosis and
SSA) but not with amyloid of AA, AL, AMed, or Aβ nature,
showing that TTR-immunoreactivity is not a general feature
of amyloid deposits.
The pancreatic tissue from the individuals with familial
TTR-amyloidosis contained varying amounts of amyloid,
irregularly distributed in the exocrine parenchyma and
surrounding connective tissue. Although amyloid was seen
very close to some pancreatic islets, TTR-amyloid did not
occur within these islets (Figure 5(b)). Neither was IAPP-
amyloid seen here.
3.4. IAPPﬁbrilsseedﬁbrilformationfromTTR
Fibril formation of many amyloid proteins, including TTR
and IAPP, occurs spontaneously in vitro after a lag phase6 Experimental Diabetes Research
which varies in length depending on protein. Seeding with
preformed ﬁbrils can shorten the lag phase considerably,
which was seen most evidently when a solution of IAPP
was seeded with IAPP ﬁbrils (Figure 6, inserted). TTR ﬁbrils
did not induce any increase in ﬂuorescence signal when
incubated with newly dissolved TTR or solubilized IAPP
(Figure 6). However, IAPP ﬁbrils had a clear eﬀect on TTR
after a lag phase of about 3 hours (Figure 6).
4. DISCUSSION
This study conﬁrms that TTR is normally expressed by
pancreatic alpha (glucagon) cells. As earlier suggested [33],
beta cells may also produce TTR but at a low degree,
not detectable by in situ hybridization. TTR is stored in
the secretory vesicles and is therefore most likely released
together with hormones at exocytosis. TTR in plasma is a
transporter of thyroxine and indirectly of retinol, but the
function of the protein in the secretory granules is unknown.
One can only speculate about the possibility that TTR binds
to the glucagon precursor and may aﬀect its processing.
IAPP and TTR are both well-known amyloid ﬁbril
proteins. Formation of amyloid ﬁbrils is a nucleation
dependent phenomenon which can be shown in vitro [14].
After a lag phase, which can last for several days, generation
of ﬁbrils usually is rapid. Seeding a ﬁbrillogenic protein
solution with preformed ﬁbrils shortens or abolishes this
lag phase. Cross-seeding, that is, the same eﬀect achieved
by addition of ﬁbrils of a diﬀerent biochemical nature, can
occur with some proteins [16]. In this study, IAPP ﬁbrils
seeded IAPP eﬃciently. This was not seen with TTR which
is in accordance with a previous report [34]. TTR ﬁbrils
did not seed IAPP but, interestingly, IAPP ﬁbrils evidently
induced ﬁbril formation from TTR. Therefore, the weak
immunoreaction of IAPP amyloid with antibodies against
TTR in some cases may indicate existence of mixed ﬁbrils
in islet deposits as a result of a speciﬁc interaction between
IAPP and TTR, although a passive diﬀusion of the latter
moleculeintotheamyloidcannotberuledout.Whileinsulin
is an inhibitor of IAPP ﬁbril formation, eﬀects of TTR is
not known. It has been suggested that molecules may exist
that lead to pathological protein folding and aggregation
and these have been called “pathological chaperones” [35].
Therefore, the possible interaction between TTR and IAPP
has to be studied further.
In the present study, we also evaluated the TTR
immunoreactivity in alpha and beta cells in conjunction
with type-2 diabetes. No such studies seem to have been
published. Generally, islets in type-2 diabetic patients con-
tained proportionally more strongly TTR-reactive cells in
accordance with the known loss of beta cells in that disease
[2, 3]. In addition, an interesting and unexpected ﬁnding
was an increased TTR immunoreactivity of beta cells in
pancreatic islets with heavy amyloid deposits. What this
means is presently not understood but we have shown
previously that IAPP in beta cells in islets with amyloid
obtains altered immunoreactive properties [32]. Thus, IAPP
immunoreactivity with a polyclonal IAPP antiserum was
lost, although labeling with a monoclonal antibody was
retained. This ﬁnding was interpreted as a sign of modiﬁ-
cation of the beta cell IAPP in type-2 diabetes. The ﬁnding
here that IAPP ﬁbrils interact with TTR is interesting in this
respect. The observation in the present study that beta cells
in amyloidotic islets are strongly TTR immunoreactive may
indicate that the intragranular milieu is altered which may
aﬀect the ability of IAPP to aggregate.
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